Effect of background long-acting beta<sub>2</sub>-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD-Reference-Cited by-同舟云学术

Effect of background long-acting beta₂-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD

Published:2018-09 Issue: Volume:Volume 13 Page:2917-2929
ISSN:1178-2005
Container-title:International Journal of Chronic Obstructive Pulmonary Disease
language:en
Short-container-title:COPD

Author:

Kerwin Edward M^ORCID,Tosiello Robert^ORCID,Price Barry,Sanjar Shahin^ORCID,Goodin Thomas

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pulmonary and Respiratory Medicine,General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression;Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation;2024

2. Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD;npj Primary Care Respiratory Medicine;2021-10-07

3. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies;International Journal of Chronic Obstructive Pulmonary Disease;2021-03

4. Use of the Evaluating Respiratory Symptoms™ in COPD as an Outcome Measure in Clinical Trials: A Rapid Systematic Review;Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation;2021

5. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials;Therapeutic Advances in Respiratory Disease;2020-01